Synthetic bronchopulmonary tetrapeptide bioregulator with epigenetic gene-regulatory and anti-inflammatory activity targeting bronchial epithelium
A synthetic tetrapeptide (H-Ala-Asp-Glu-Leu-OH; ADEL) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as an ultrashort peptide bioregulator with bronchopulmonary tissue-specific proliferative, anti-inflammatory, and epithelial-regenerative activity targeting bronchial epithelium, ciliated cell restoration, and respiratory mucosal barrier function.
Abstract
Bronchogen (H-Ala-Asp-Glu-Leu-OH; ADEL tetrapeptide; molecular formula C18H30N4O9; molecular weight 446.45 g/mol) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as the bronchopulmonary-specific member of the Khavinson ultrashort peptide bioregulator family [1, 2]. The compound belongs to a class of synthetic two-to-seven-residue peptide sequences modeled on tissue-specific peptide fragments isolated from mammalian organ extracts, and is designated as the respiratory system bioregulator within this peptide family. Bronchogen is structurally related to but distinct from the other Khavinson tetrapeptides that share the Ala-Glu-Asp tripeptide core (Cardiogen, Cortagen, Epithalon); the ADEL sequence carries a different arrangement of the acidic residues (Asp at position two, Glu at position three) and a hydrophobic leucine residue at the C-terminus, a configuration that determines bronchial tissue specificity within the Khavinson classification system [3, 4]. The principal molecular mechanism of Bronchogen, characterized through molecular modeling, cell culture, organotypic bronchial tissue studies, and animal models of obstructive lung disease, is epigenetic regulation of gene expression through direct interaction of the tetrapeptide with double-stranded DNA and with histone proteins, producing chromatin remodeling and reactivation of transcriptional programs in bronchial epithelial cells [5, 6, 7]. The bronchopulmonary activity, characterized in organotypic lung tissue cultures from young and aged rats, human bronchial epithelial cell cultures across multiple passages, and nitrogen dioxide-induced chronic obstructive pulmonary disease (COPD) rat models, includes stimulation of bronchial epithelial cell proliferation and differentiation with upregulation of differentiation markers in aging cell cultures [8, 9], regulation of Ki67, Mcl-1, p53, CD79, and endothelial nitric oxide synthase (NOS-3) protein expression in human bronchial epithelium [5], restoration of normal ciliated epithelial architecture with reduction of goblet cell hyperplasia and squamous metaplasia in COPD models [10], normalization of proinflammatory cytokine profiles and neutrophilic inflammation in bronchoalveolar lavage fluid [10, 11], and enhancement of secretory immunoglobulin A and surfactant protein B production indicating recovery of respiratory mucosal barrier and surfactant function [11]. No formal pharmacokinetic studies have been published for Bronchogen as the isolated synthetic ADEL tetrapeptide. As a linear tetrapeptide with unprotected termini, the compound is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid; however, molecular modeling studies have demonstrated that ultrashort peptides are substrates of the proton-coupled oligopeptide transporter (PEPT1/PEPT2) family carriers, supporting intestinal absorption and cellular uptake through active transport mechanisms [12, 13]. No human clinical trials have been published. The compound is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. Bronchogen is registered in the Russian Federation as a biologically active additive and is commercially available there in capsule formulations. It is supplied internationally as a research-grade lyophilized peptide by multiple peptide synthesis vendors at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
A Khavinson-class synthetic tripeptide bioregulator derived from vascular wall protein sequences, characterized by epigenetic modulation of endothelial proliferation markers, endothelin-1 normalization, sirtuin-1 upregulation, and neuroprotective gene regulation in preclinical aging and Alzheimer’s disease models.
Abstract
Vesugen (Lys-Glu-Asp; KED) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson as part of a decades-long program investigating short-chain peptide regulation of age-associated tissue decline. The compound belongs to the Khavinson class of ultrashort (two to four amino acid residue) bioregulatory peptides, a family of synthetic sequences derived from organ-specific protein fractions that are proposed to penetrate cell nuclei and modulate gene expression through direct interactions with DNA promoter regions and epigenetic regulatory mechanisms. Vesugen is the synthetic analog corresponding to the vascular-wall-derived peptide fraction originally isolated as the active component of Ventfort, a polypeptide complex extracted from bovine aortic tissue. The tripeptide sequence Lys-Glu-Asp was identified as the minimal bioactive motif responsible for the vasoprotective activity of the parent extract.
The molecular pharmacology of Vesugen is characterized by epigenetic modulation of vascular endothelial cell function. In dissociated human endothelial cell cultures, Vesugen stimulates synthesis of the proliferation-associated protein Ki-67, the expression of which declines during cellular aging [1]. Molecular docking studies demonstrate that Vesugen binds to the promoter region of the MKI67 gene, making contact through the CATC sequence at the core promoter located between positions -14 and +12 relative to the transcription initiation site [1]. In models of atherosclerotic and restenotic endothelium in vitro, Vesugen normalizes the expression of endothelin-1, restores connexin (Cx37, Cx43) expression for intercellular communication, and increases sirtuin-1 (SIRT1) expression, implicating the compound in DNA repair and cellular longevity pathways [2, 3]. The compound also modulates expression of vascular endothelial growth factor (VEGF) and the apoptosis marker p53, contributing to a net pro-proliferative and anti-apoptotic phenotype in aged vascular endothelial cells.
Beyond its primary vascular target, Vesugen has demonstrated neuroprotective activity in several preclinical models. The tripeptide regulates expression of cell aging and apoptosis genes (p16, p21), neuronal differentiation genes and proteins (NES, GAP43, nestin), and genes implicated in Alzheimer’s disease pathogenesis (SUMO, APOE, IGF1) [4]. In hippocampal neuron cultures exposed to amyloid-beta synaptotoxicity, Vesugen increased the number of mushroom-type dendritic spines by 20 percent [5]. Oral administration of Vesugen improved memory and attention in elderly individuals with functional central nervous system disorders in a small clinical cohort [4]. In a 32-patient clinical study of elderly individuals with chronic polymorbidity and organic brain syndrome, Vesugen demonstrated anabolic properties and improved central nervous system activity, slowing the rate of aging as measured by biological age indicators [6].
The compound is not approved by any national regulatory authority as a pharmaceutical product. It is supplied as a research-grade synthetic peptide and as a dietary supplement (capsule form) in certain jurisdictions. The primary literature on Vesugen originates predominantly from Russian research institutions, principally the Saint Petersburg Institute of Bioregulation and Gerontology and affiliated laboratories. Independent replication by Western laboratories using contemporary structural biology and pharmacology methodologies remains limited. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Polypeptide bioregulator complex derived from cerebral cortex with neurotrophic, neuroprotective, and nootropic activity
A heterogeneous low-molecular-weight neuropeptide preparation extracted from the cerebral cortex of young cattle and pigs, registered in the Russian Federation as a neuroprotective agent for cerebrovascular disorders, traumatic brain injury, cognitive impairment, and perinatal central nervous system lesions, distinguished from Cerebrolysin by cortex-specific sourcing and intramuscular administration.
Abstract
Cortexin is a lyophilized complex of water-soluble polypeptide fractions with molecular weights ranging from 1,000 to 10,000 Daltons, obtained by acetic acid extraction from the cerebral cortex of cattle and pigs younger than 12 months of age. The preparation contains predominantly acidic and neutral polypeptides (70 to 95 percent of total mass), free amino acids (including glutamic acid, aspartic acid, glycine, serine, lysine, and alanine as quantitatively predominant species), and trace quantities of vitamins, minerals, and fatty acids. Unlike single-sequence peptide therapeutics, Cortexin is a heterogeneous mixture without a defined primary structure, and its pharmacological activity is attributed to the collective action of multiple bioactive peptide fractions rather than to any single molecular entity.
The compound was developed within the Soviet and subsequently Russian bioregulator research program led by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology beginning in the 1980s, with the first clinical applications in military and aerospace medicine. The compound is registered in Russia, Ukraine, Kazakhstan, Belarus, Uzbekistan, and several other Commonwealth of Independent States jurisdictions for the treatment of acute and chronic cerebrovascular disorders, traumatic brain injury, cognitive impairment, encephalopathy of various origins, epilepsy as adjunctive therapy, and perinatal central nervous system lesions in children. It is not registered or approved in the European Union, the United States, Japan, or any jurisdiction with International Council for Harmonisation regulatory standards.
The molecular mechanisms of Cortexin are pleiotropic and incompletely characterized at the individual peptide level. Demonstrated activities include modulation of glutamatergic transmission through interaction with AMPA receptors, kainate receptors, and metabotropic glutamate receptors (mGluR1 and mGluR5); GABAergic modulation through GABA-A receptor binding; activation of neurotrophic signaling cascades including brain-derived neurotrophic factor and nerve growth factor pathways; antioxidant activity through restoration of pro-oxidant and antioxidant system balance; anti-inflammatory action at both cerebral and systemic levels; and anti-apoptotic effects on neurons under ischemic and excitotoxic stress. Radioactively labeled Cortexin peptides have been demonstrated to cross the blood-brain barrier in mice, supporting direct central nervous system activity. Neuron-specific proteins including beta-5-tubulin, creatine kinase B, and protein 14-3-3 alpha/beta have been identified as molecular partners of Cortexin peptides in brain tissue.
The clinical evidence base for Cortexin is substantial within the Russian-language medical literature but limited in the international peer-reviewed literature. A multicenter study of cognitive dysfunction in children demonstrated improvement in attention, visual memory, and thinking in pediatric patients with consequences of perinatal central nervous system lesions. In cerebral palsy with comorbid epilepsy, Cortexin as adjunctive therapy reduced seizure frequency by more than two-fold in 36.9 percent of patients while improving motor function. Comparative preclinical studies have demonstrated neuroprotective efficacy comparable to Cerebrolysin and superior to Actovegin in rat models of acute and chronic brain ischemia. A systematic review of animal-derived nootropics noted that the limited number of eligible Cortexin studies precluded meta-analysis, though available data suggested potential efficacy with no safety concerns. The compound is generally well tolerated; the principal adverse events are injection site reactions (8 to 15 percent), headache (5 to 12 percent), dizziness (3 to 8 percent), and rare hypersensitivity reactions including anaphylaxis. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Synthetic bioregulatory tripeptide (Glu-Asp-Arg) with proposed epigenetic neuromodulatory activity
A synthetic tripeptide bioregulator derived from the pineal gland peptide fraction, investigated as a neuroepigenetic modulator of gene expression with reported neuroprotective, antioxidant, and geroprotective activity in preclinical oxidative stress, ischemia, and neurodegeneration models.
Abstract
Pinealon (EDR peptide; L-glutamyl-L-aspartyl-L-arginine) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson as part of a multigenerational program to identify tissue-specific short-chain peptides capable of modulating gene expression through direct interaction with chromatin. The compound was identified as one of the shortest biologically active sequences within Cortexin, a complex peptide fraction extracted from bovine cerebral cortex tissue that has been used clinically in several post-Soviet jurisdictions for the treatment of traumatic brain injury, ischemic stroke, and cognitive impairment. Pinealon was subsequently synthesized as a standalone tripeptide and advanced through a series of in vitro and in vivo investigations spanning antioxidant activity, neuroprotection, serotonin biosynthesis regulation, dendritic spine preservation in Alzheimer’s disease models, and preliminary open-label clinical observations in elderly patients with cognitive decline and in patients recovering from craniocerebral trauma.
The proposed mechanism of action is unconventional relative to classical receptor-mediated peptide pharmacology. Due to its low molecular weight (418.41 g/mol) and cationic character, Pinealon is reported to penetrate lipid bilayers and nuclear membranes without requiring surface receptor engagement, gaining direct access to chromatin. Molecular modeling and in vitro binding studies from the Khavinson laboratory have identified complementary binding sites in the promoter regions of several genes relevant to neuroprotection and neurodegeneration, including TPH1 (tryptophan hydroxylase 1, the rate-limiting enzyme in serotonin biosynthesis), SOD2 (mitochondrial superoxide dismutase), GPX1 (glutathione peroxidase 1), PPARA and PPARG (peroxisome proliferator-activated receptor alpha and gamma), CASP3 (caspase-3), and APOE (apolipoprotein E). The proposed binding occurs at specific DNA sequences, principally d(CCTGCC)2 and d(CCAGC)2, through sequence-specific steric and electrostatic complementarity with the major groove of double-stranded DNA. The functional consequence is reported to be destabilization of local DNA secondary structure, alteration of histone modification patterns, and increased accessibility of regulatory regions to transcription factors, resulting in upregulation of neuroprotective gene products and downregulation of pro-apoptotic pathways.
Preclinical pharmacology studies, conducted predominantly by the Khavinson group and affiliated Russian laboratories, have reported that Pinealon produces dose-dependent suppression of reactive oxygen species accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells; increases cell viability under oxidative stress conditions; delays ERK1/2 activation in neurons exposed to homocysteine; reduces caspase-3 expression and p53 protein synthesis in brain tissue; increases serotonin synthesis in neuronal cultures of rat cerebral cortex; normalizes superoxide dismutase and glutathione peroxidase activity in the brains of hypoxia-sensitive rats; prevents the loss of mushroom-shaped dendritic spines in hippocampal neurons from 5xFAD transgenic mice (a model of familial Alzheimer’s disease); and protects rat offspring from prenatal hyperhomocysteinemia-induced cognitive deficits. In an open-label clinical observation in 72 patients with traumatic brain injury, addition of Pinealon to standard rehabilitation therapy improved memory function in approximately 59 percent of patients.
No completed, peer-reviewed randomized controlled trial of Pinealon has been published in English-language indexed journals as of the date of this monograph. No Phase 1 formal safety study, no Phase 2 efficacy trial, and no Phase 3 registration study exist in any population. The compound has no approved indication in any jurisdiction recognized by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Virtually all published Pinealon research originates from the Khavinson laboratory and closely affiliated institutions; independent replication by Western academic laboratories is absent. The chromatin-interaction model, while supported by computational molecular modeling and fluorescence microscopy studies from the originating group, has not been independently validated by structural biology methods (X-ray crystallography, cryo-electron microscopy) at the resolution required to confirm the proposed binding geometry. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Benzylpiperazine-aminopyridine neurogenic compound with indirect brain-derived neurotrophic factor modulation and hippocampal neurogenesis stimulation
A first-in-class small molecule neurogenic agent discovered through phenotypic screening of human hippocampal neural stem cells, developed for major depressive disorder and under investigation for cognitive impairment, diabetic neuropathy, and post-traumatic stress disorder.
Abstract
NSI-189 (amdiglurax; ALTO-100) is a benzylpiperazine-aminopyridine small molecule identified through a phenotypic screen of approximately 10,000 compounds against human hippocampal neural stem cells and advanced as a first-in-class hippocampal neurogenesis stimulator for the treatment of major depressive disorder (MDD). The compound was discovered by Karl Johe and colleagues at Neuralstem, Inc. (Germantown, Maryland) and is now under development by Alto Neuroscience (Mountain View, California) under the designation ALTO-100. NSI-189 is mechanistically distinct from all marketed antidepressants: it has no detectable activity at serotonin, norepinephrine, or dopamine transporters, no binding at 52 standard neurotransmitter receptor and ion channel targets, and no activity across a panel of 900 kinases. The morphological effects are confined to the dentate gyrus of the hippocampus and the subventricular zone; no structural changes have been observed elsewhere in the brain.
Clinical development has proceeded through Phase 1 (41 healthy volunteers, 2011), Phase 1b (24 MDD patients, Fava et al. 2016, published in Molecular Psychiatry), and Phase 2 (220 MDD outpatients, Papakostas et al. 2020, published in Molecular Psychiatry). Hippocampal volume was not significantly changed in MDD patients at the studied doses and duration, despite the robust preclinical volumetric signal.
Alto Neuroscience acquired the NSI-189 program in October 2021 and redesignated the compound ALTO-100. A Phase 2b trial (301 adults with MDD, 34 U.S. sites, 6 weeks, biomarker-enriched design using a cognitive memory test) reported topline results in 2024: ALTO-100 did not demonstrate statistically significant improvement in MADRS versus placebo in the biomarker-defined population and did not meet secondary endpoints. The compound was well tolerated, with headache, nausea, and abnormal dreams as the most common adverse events at rates similar to placebo. A Phase 2b trial in bipolar depression is expected to report in 2026, and the compound remains under investigation for post-traumatic stress disorder.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
A first-in-class triazinetrione pan-Trk positive allosteric modulator developed by AlzeCure Pharma that enhances BDNF and NGF signaling for the treatment of cognitive dysfunction in Alzheimer’s disease, with additional preclinical support for depression, traumatic brain injury, and sleep disorders.
Abstract
ACD856 is a novel, orally bioavailable triazinetrione compound functioning as a positive allosteric modulator (PAM) of the tropomyosin receptor kinases TrkA, TrkB, and TrkC, the principal signal-transducing receptors for the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3), respectively [1, 2]. The compound was identified through a high-throughput screening campaign of approximately 25,000 compounds and structurally optimized from the veterinary antiparasitic triazinetrione scaffold shared by toltrazuril and ponazuril (ACD855), with the critical improvement of a substantially shortened elimination half-life suitable for once-daily human dosing [3, 4]. ACD856 potentiates the tropomyosin receptor kinases with EC50 values of 382 nM (TrkA), 295 nM (TrkB), and approximately 330 nM (TrkC), and exhibits additional positive allosteric modulation of the insulin-like growth factor 1 receptor (IGF1R) and fibroblast growth factor receptor 1 (FGFR1) [1, 5]. The mechanism of action is distinct from orthosteric Trk agonism: ACD856 binds the intracellular kinase domain of Trk receptors and increases the maximal catalytic velocity (Vmax) of the kinase, thereby amplifying endogenous neurotrophin signaling rather than substituting for it [2, 6]. This allosteric mechanism preserves the spatiotemporal specificity of native neurotrophin activity, a property expected to confer a more favorable safety profile than direct agonist approaches that have historically been limited by pain, hyperalgesia, and off-target proliferative effects.
In preclinical pharmacology, ACD856 has demonstrated reversal of scopolamine-induced and dizocilpine (MK-801)-induced memory impairment in passive avoidance and novel object recognition tasks in mice, restoration of age-related memory deficits in 21-month-old mice to the performance level of young animals following single-dose administration, neuroprotection against amyloid-beta(1-42)-induced synaptotoxicity in primary cortical neurons, enhancement of NGF-stimulated neurite outgrowth in PC12 cells, elevation of BDNF protein levels in the brains of aged mice following repeated dosing, and sustained antidepressant-like effects in the forced swim test persisting up to seven days after the last dose [5, 7, 8]. The compound also enhanced mitochondrial ATP production under energy-deprived conditions, increased phosphorylation of TrkB and ERK1/2 in cortical neurons, elevated hippocampal concentrations of serotonin, noradrenaline, and dopamine by in vivo microdialysis, and increased expression of the presynaptic protein SNAP25, collectively indicating a broad neuroprotective and neuroplasticity-promoting pharmacological profile [5, 7].
ACD856 has completed two Phase 1 clinical studies in healthy volunteers. AlzeCure Pharma has received a EUR 2.5 million grant from the European Innovation Council to conduct a Phase IIa clinical study of ACD856 in Alzheimer’s disease, with higher doses to be evaluated based on the favorable Phase 1 safety profile [12]. Additional indications under preclinical investigation include depressive disorders, traumatic brain injury, sleep disorders, and postoperative cognitive dysfunction.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Thymic polypeptide bioregulator complex with immunomodulatory and geroprotective activity
A heterogeneous polypeptide complex isolated from calf thymus, developed at the Military Medical Academy in Leningrad as a thymic bioregulator for immune restoration, distinguished from other thymic peptide preparations by its multicomponent composition containing the immunomodulatory dipeptides L-glutamyl-L-tryptophan and L-lysyl-L-glutamic acid and the tripeptide L-glutamyl-L-aspartyl-L-proline.
Abstract
Thymalin is a standardized polypeptide complex isolated from the thymus gland of calves by acid hydrolysis and ultrafiltration, containing peptide fractions in the 1,000 to 10,000 dalton molecular weight range. Developed at the Military Medical Academy in Leningrad (now Saint Petersburg) by Vladimir Khavinson and Vyacheslav Morozov in the 1970s, the preparation was registered as an immunomodulatory pharmaceutical in the Soviet Union in 1982 and has remained in clinical use in the Russian Federation for more than four decades. Unlike the structurally defined thymic peptides thymosin alpha-1 (a 28-amino-acid single-sequence peptide), thymulin (a zinc-dependent nonapeptide), and thymopentin (a synthetic pentapeptide fragment of thymopoietin), Thymalin is a multicomponent extract whose principal bioactive constituents have been identified by reversed-phase high-performance liquid chromatography as the dipeptide L-glutamyl-L-tryptophan (Glu-Trp, subsequently developed independently as Thymogen), the dipeptide L-lysyl-L-glutamic acid (Lys-Glu, developed as Vilon), and the tripeptide L-glutamyl-L-aspartyl-L-proline (Glu-Asp-Pro, developed as Crystagen). The molecular mechanism of the immunoprotective activity is attributed to the capacity of these short peptides to bind selectively to double-stranded DNA sequences and to histone proteins, thereby modulating chromatin conformation, gene expression, and the synthesis of immune system proteins including interleukins, interferons, heat-shock proteins, and components of the fibrinolytic system. In experimental systems, Thymalin stimulates the differentiation and functional activity of T-lymphocyte subpopulations (CD4+ and CD8+), normalizes the ratio of T-helper to T-suppressor cells, enhances natural killer cell activity and phagocytosis, and modulates the balance between pro-inflammatory and anti-inflammatory cytokines. The geroprotective properties of Thymalin are supported by a prospective clinical observation of 266 elderly subjects over 6 to 8 years conducted at the St. Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences, in which Thymalin-treated subjects exhibited 2.0- to 2.1-fold lower mortality compared to controls receiving standard geriatric care, with further reductions (4.1-fold lower mortality) observed in a subgroup receiving annual combined Thymalin and Epithalamin treatment for 6 years. In vitro studies have demonstrated that Thymalin reduces expression of the stem cell markers CD44 and CD117 by 2- to 3-fold while increasing expression of CD28 (a marker of mature T lymphocytes) by 6.8-fold, consistent with stimulation of hematopoietic stem cell differentiation into functional T cells. The safety record across more than 40 years of clinical use indicates minimal adverse events, principally limited to injection-site reactions. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Type I transmembrane protein and circulating endocrine factor of the glycosyl hydrolase family 1 superfamily with obligate FGF23 co-receptor and pleiotropic anti-aging functions
A kidney-derived transmembrane glycoprotein and its shed soluble ectodomain, identified through insertional mutagenesis in 1997 as a suppressor of aging phenotypes in mice, functioning both as an obligate co-receptor for fibroblast growth factor 23 in mineral metabolism and as a circulating endocrine factor that inhibits insulin/IGF-1, Wnt, TGF-beta, and NF-kappaB signaling pathways with demonstrated neuroprotective, cardioprotective, and renoprotective activity in preclinical models.
Abstract
Alpha-Klotho (alpha-KL) is a 130 kDa type I single-pass transmembrane protein encoded by the KL gene on human chromosome 13q13.1, first identified in 1997 by Kuro-o et al. through characterization of an insertional mutation in mice that produced a syndrome of accelerated aging encompassing soft tissue calcification, arteriosclerosis, skin atrophy, osteoporosis, emphysema, gonadal dysplasia, and dramatically shortened lifespan [1]. The protein comprises a short intracellular domain, a single transmembrane helix, and a large extracellular region containing two tandem glycosyl hydrolase family 1 (GH1) domains, designated KL1 and KL2, which share sequence homology with family 1 beta-glucosidases but lack catalytic activity against conventional substrates due to substitutions in the active-site residues. The extracellular domain undergoes proteolytic shedding by ADAM10, ADAM17, and BACE1, generating a soluble ectodomain (sKL) comprising KL1 and KL2 that circulates as an endocrine factor detectable in plasma, cerebrospinal fluid, and urine. A shorter secreted isoform containing only KL1 is produced by alternative mRNA splicing.
In its membrane-bound form, alpha-Klotho functions as an obligate co-receptor for fibroblast growth factor 23 (FGF23), forming a ternary complex with FGF receptor 1c (FGFR1c) that is essential for phosphaturic signaling in the renal proximal tubule and for suppression of 1,25-dihydroxyvitamin D3 (calcitriol) synthesis. The crystal structure of the alpha-Klotho/FGFR1c/FGF23 ternary complex, resolved by Chen et al. (2018) at 3.0 angstrom resolution, demonstrated that the KL2 domain of alpha-Klotho cradles FGF23 with a receptor-binding arm extending from the KL1-KL2 interdomain cleft, creating a composite binding surface for FGF23 engagement [2]. Loss of this co-receptor function produces the hyperphosphatemia, hypervitaminosis D, and ectopic calcification that characterize the kl/kl mouse phenotype and that are recapitulated in FGF23 knockout mice.
Independent of the FGF23 co-receptor function, soluble alpha-Klotho acts as a circulating endocrine factor with pleiotropic anti-aging activity. Characterized signaling activities include inhibition of the insulin/insulin-like growth factor 1 (IGF-1) pathway through suppression of receptor autophosphorylation; suppression of Wnt/beta-catenin signaling through direct binding to Wnt ligands; inhibition of transforming growth factor beta (TGF-beta) type II receptor signaling and downstream Smad phosphorylation; suppression of NF-kappaB-driven inflammatory transcription; and regulation of ion channel and transporter activity in the renal tubule, including TRPV5, TRPV6, ROMK1, and the Na+/K+-ATPase [3, 4, 5]. These FGF23-independent activities are the molecular basis for the broader anti-aging, neuroprotective, cardioprotective, and anti-fibrotic effects observed in gain-of-function and supplementation studies.
Circulating soluble alpha-Klotho levels decline with age in humans, beginning approximately in the fourth decade of life, and are markedly reduced in chronic kidney disease, where loss of renal alpha-Klotho expression precedes and contributes to the mineral and bone disorder, cardiovascular calcification, and accelerated aging phenotype of uremia [6]. Epidemiological studies have identified inverse associations between circulating soluble alpha-Klotho concentrations and all-cause mortality, cardiovascular events, and cognitive decline in community-dwelling older adults [7]. The KL-VS haplotype (defined by the F352V and C370S variants, rs9536314 and rs9527025) has been associated in some cohorts with altered klotho secretion, cortical brain volume, and cognitive resilience in aging, though replication across large cohorts remains inconsistent [8, 9].
Preclinical studies have demonstrated that recombinant alpha-Klotho protein administration, adeno-associated virus-mediated KL gene transfer, and transgenic KL overexpression produce renoprotection in ischemia-reperfusion injury and unilateral ureteral obstruction models; cardioprotection with attenuation of left ventricular hypertrophy and fibrosis; suppression of vascular calcification; and cognitive enhancement in aged, young, and alpha-synuclein transgenic mice through NMDA receptor-dependent glutamatergic mechanisms [10, 11, 12, 13]. A 2023 study in aged nonhuman primates demonstrated that a single subcutaneous injection of a klotho protein fragment enhanced spatial and working memory, representing the first primate cognitive enhancement data for the compound [14].
As of 2026, alpha-Klotho is in early clinical development. Klothea Bio launched a Phase 1b randomized, double-blind, placebo-controlled trial of AKL003, an alpha-Klotho mRNA therapeutic administered intravenously, in healthy adult volunteers in February 2026. Klotho Neurosciences is advancing KLTO-202, a KL gene therapy, toward first-in-human studies for amyotrophic lateral sclerosis. No alpha-Klotho protein or gene therapy product has received regulatory approval in any jurisdiction. Recombinant human alpha-Klotho protein is available from multiple research suppliers (R&D Systems, Abcam, Sino Biological, Thermo Fisher) for in vitro and preclinical applications. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Endogenous bioactive peptide agonist of the apelin receptor (APJ/APLNR), a class A G protein-coupled receptor
A pyroglutamyl-modified tridecapeptide derived from the C-terminus of preproapelin, identified as the predominant circulating isoform and the highest-potency endogenous agonist of the APJ receptor, with characterized cardiovascular inotropic, vasodilatory, aquaretic, metabolic, and neuroprotective activities.
Abstract
Apelin-13, the C-terminal tridecapeptide fragment of the 77-amino-acid preproapelin precursor, is the most potent endogenous agonist of the apelin receptor (APJ, also designated APLNR), a class A rhodopsin-like G protein-coupled receptor originally cloned as an orphan receptor in 1993 by O’Dowd et al. on the basis of sequence homology with the angiotensin II type 1 receptor. The receptor was deorphanized in 1998 by Tatemoto and colleagues at the Takeda Chemical Research Institute, who isolated apelin from bovine stomach extracts using an extracellular acidification assay on APJ-expressing Chinese hamster ovary cells and demonstrated that apelin-13 displayed 8- to 60-fold higher potency than the longer apelin-36 isoform. The predominant circulating form in human plasma is [Pyr1]apelin-13 (pyroglutamyl apelin-13), in which the N-terminal glutamine residue undergoes spontaneous or enzymatic cyclization to pyroglutamate, conferring modest resistance to aminopeptidase degradation and representing the principal bioactive isoform in cardiovascular tissue and plasma.
Apelin-13 activates APJ with sub-nanomolar potency (EC50 approximately 0.37 nM in cellular acidification assays), coupling predominantly through Gi/o proteins to inhibit adenylyl cyclase and reduce intracellular cAMP, through Gq/11 to activate phospholipase C and mobilize intracellular calcium, and through G12/13 to engage RhoA-dependent cytoskeletal rearrangement. The receptor also recruits beta-arrestin 1 and 2, mediating receptor internalization and activating extracellular signal-regulated kinase 1/2 (ERK1/2) through G protein-independent pathways. The downstream signaling cascade includes activation of phosphoinositide 3-kinase (PI3K)/Akt, endothelial nitric oxide synthase (eNOS), AMP-activated protein kinase (AMPK), and inhibition of reactive oxygen species generation, collectively producing the cardiovascular, metabolic, and cytoprotective effects that define the pharmacological profile.
The cardiovascular pharmacology of apelin-13 is the most extensively characterized domain. In human clinical studies, systemic infusion of [Pyr1]apelin-13 at 30 to 300 nmol/min produces a sustained approximately 10 percent increase in cardiac index, increased ejection fraction, reduced systemic vascular resistance by approximately 12 percent, and reduced mean arterial pressure by approximately 4 percent, effects observed in both healthy volunteers and patients with chronic heart failure and chronic kidney disease. The mechanism involves direct positive inotropic action on cardiomyocytes through APJ-mediated calcium sensitization, nitric oxide-dependent vasodilation in resistance arteries, and counter-regulatory opposition to the renin-angiotensin-aldosterone system. Preclinical models demonstrate cardioprotective effects in myocardial infarction, ischemia-reperfusion injury, pressure-overload hypertrophy, and diabetic cardiomyopathy, with mechanisms including salvage of the peri-infarct border zone, mobilization of endogenous cardiac stem cells, and suppression of pathological fibrosis.
The renal pharmacology is defined by the functional antagonism between apelin and arginine vasopressin (AVP) at the collecting duct. Apelin-13 inhibits vasopressin-induced translocation of aquaporin 2 (AQP2) water channels to the apical membrane of principal cells through Gi-mediated inhibition of cAMP/protein kinase A signaling, producing a diuretic (aquaretic) effect that opposes AVP-driven water reabsorption. This reciprocal regulation positions the apelin/AVP axis as a physiological rheostat for water homeostasis, with therapeutic implications for hyponatremia and states of AVP excess.
Metabolic pharmacology encompasses insulin-sensitizing and glucoregulatory effects. Apelin-13 administration in diabetic rodent models reduces blood glucose, increases serum insulin, improves pancreatic islet mass, and enhances glucose uptake in skeletal muscle through AMPK-dependent GLUT4 translocation. Neuroprotective activity has been demonstrated in models of ischemic stroke, diabetes-associated cognitive decline, and excitotoxic injury, with mechanisms including antioxidant defense through the SIRT3/FoxO3 pathway, anti-inflammatory cytokine modulation, and direct neuronal survival signaling through PI3K/Akt.
The principal pharmacokinetic limitation of apelin-13 is its extremely short plasma half-life. Native [Pyr1]apelin-13 has a plasma half-life of approximately 21 to 24 minutes in rodents, driven by rapid proteolytic degradation at the Leu5-Ser6 peptide bond by neprilysin, angiotensin-converting enzyme 2 (ACE2), and plasma kallikrein. This has motivated extensive medicinal chemistry efforts to develop stabilized analogues (macrocyclic peptides, D-amino acid substitutions, PEGylation) and small-molecule APJ agonists (AMG-986, BMS-986224, azelaprag) for chronic administration.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.
Selective kappa-opioid receptor (KOR) antagonist with short-acting, non-inactivating pharmacodynamic profile
A potent, orally bioavailable aminobenzyloxyarylamide kappa-opioid receptor antagonist developed at Eli Lilly and advanced through Phase 3 clinical evaluation for adjunctive treatment of major depressive disorder with anhedonia, distinguished from earlier KOR antagonists by favorable drug-like properties, short-acting receptor blockade, and a well-characterized safety profile.
Abstract
Aticaprant (LY-2456302, CERC-501, JNJ-67953964) is a potent, selective, orally bioavailable antagonist of the kappa-opioid receptor (KOR) with a binding affinity (Ki) of 0.81 nM, approximately 30-fold selectivity over the mu-opioid receptor (Ki = 24.0 nM), and approximately 190-fold selectivity over the delta-opioid receptor (Ki = 155 nM). The compound belongs to the aminobenzyloxyarylamide chemical class and was designed at Eli Lilly Research Laboratories as a clinically viable therapeutic targeting the endogenous dynorphin/KOR neuromodulatory system, a pathway implicated in the pathophysiology of stress-induced anhedonia, dysphoria, and addictive behaviors. In contrast to earlier KOR antagonists such as JDTic and nor-binaltorphimine, which exhibit ultra-long-duration receptor inactivation persisting for weeks after a single dose, aticaprant produces short-acting, reversible KOR blockade with an elimination half-life of 30 to 40 hours, enabling conventional once-daily oral dosing and predictable pharmacokinetic management.
In rodent behavioral models, aticaprant produced antidepressant-like effects in the mouse forced swim test, enhanced the efficacy of imipramine and citalopram, reduced ethanol self-administration in alcohol-preferring (P) rats, and reversed unpredictable chronic mild stress-induced anhedonia in C57BL/6J mice, as measured by sucrose preference, nest building, and forced swim endpoints.
Clinical development of aticaprant has proceeded through multiple sponsors. Eli Lilly conducted the initial Phase 1 single- and multiple-ascending dose studies (Lowe et al. 2014), establishing safety, tolerability, and the absence of clinically significant interactions with ethanol. Cerecor Inc. acquired the compound in 2015 and initiated early clinical studies in mood and substance use disorders. Janssen Pharmaceuticals (Johnson and Johnson) acquired the compound in 2017 and advanced it through Phase 2 and Phase 3 programs for adjunctive treatment of major depressive disorder (MDD) in patients with inadequate response to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). The Phase 2 randomized, double-blind, placebo-controlled study (Jacobsen et al. 2024) in 181 participants with MDD and moderate-to-severe anhedonia demonstrated a statistically significant reduction of 2.1 points on the Montgomery-Asberg Depression Rating Scale (MADRS) for aticaprant 10 mg versus placebo (p = 0.04), with favorable tolerability and no new safety signals. However, the compound did not separate from placebo on secondary measures of anhedonia (Snaith-Hamilton Pleasure Scale), global illness severity (CGI-S), anxiety (HAM-A), or patient-reported depression outcomes.
Janssen subsequently initiated the VENTURA Phase 3 program comprising five pivotal trials in MDD with anhedonia. On 6 March 2025, Johnson and Johnson announced discontinuation of the VENTURA program due to insufficient efficacy in the target population, while noting that the compound remained safe and well tolerated with no new safety signals detected. The most common treatment-emergent adverse events in clinical trials were headache (11.8% versus 7.1% placebo), diarrhea (8.2% versus 2.4%), nasopharyngitis (5.9% versus 2.4%), and pruritus (5.9% versus 0%). Johnson and Johnson has indicated that it will explore future development opportunities for aticaprant in other areas of high unmet need. The compound is not approved by any regulatory authority for any indication. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.